Navigation Links
CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
Date:11/7/2007

SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the quarter ended September 30, 2007 on Tuesday, November 13, 2007 after the close of the U.S. financial markets.

CryoCor will also hold a Web cast and conference call at 5:00 p.m. ET / 2:00 p.m. PT on November 13, 2007. Management will discuss the financial results, recent regulatory and clinical activities, its intellectual property strategy and the status of its commercial launch of the Company's Cardiac Cryoablation System for the treatment of right atrial flutter.

The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com.

After the live Web cast, the call will remain available on CryoCor's Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 260426.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Contacts:

CryoCor The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow

Chief Financial Officer (investors)

(858) 909-2200 (646) 536-7030 / 7020

gtibbitts@cryocor.com nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
2. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
3. CryoCor Appoints New Vice President of Sales and Marketing
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: